Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.37), $0.06 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $1 million versus the consensus estimate of $1.18 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.